? IMMUNOLOGY AND IMMUNOTHERAPY PROGRAM The Immunology and Immunotherapy of Cancer Program (IM) represents a merger of the former Cancer Immunology and Immunotherapy and the Hematopoietic Cell Transplantation and Immune Reconstitution Programs that took place with the approval of the External Advisory Board in 2012. The major overall goals of the program are to understand the nature of the immune system and its response to malignancies and to explore auto- and allo-immune responses to cancer with the goal of enabling the discovery and development of more effective anti-tumor immunotherapy. These goals will be achieved by fostering collaborative research, advancing the latest technologies to probe immunological mechanisms, and by enhancing the infrastructure for clinical translation. Research by program members has resulted in exciting new developments in both understanding immune function and developing novel therapies. Advances include the development and application of CyTOF and high throughput sequencing for evaluating cellular function and responses and the translation of important concepts to the clinic in promising early phase clinical trials Co-led by Robert Negrin, MD and Edgar Engleman, MD, the 32 members of the program represent nine departments in the School of Medicine. Program members are major participants in one NCI P01, a number of NCI R01s, R21 and R33 and a NIH T32. Peer-reviewed funding is represented by a total of $12.2M in total costs/year of which $2.4M is from the NCI, $5.5M from other NIH Institutes, and $4.4M from other peer-reviewed sources. During the past five years, over 300 papers have been published, of which 22% are intra-programmatic and 32% inter-programmatic. Many of these manuscripts reflect external collaborations. Future aims include the use of new technologies to analyze the immune responses to tumors and the development of novel cellular therapeutic and other immunological interventions including CD8+ memory T cells, cytokine-induced killer (CIK) cells, CAR T cells and other genetically engineered cellular and biological therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA124435-11S2
Application #
9784140
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Belin, Precilla L
Project Start
Project End
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
11
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442

Showing the most recent 10 out of 322 publications